 |
|
Insurance Coverage, Physician Recommendations, and Access to Emerging Treatments
Growth Hormone Therapy for Childhood Short Stature
Beth S. Finkelstein, PhD;
J. B. Silvers, PhD;
Ursula Marrero, MSSA;
Duncan Neuhauser, PhD;
Leona Cuttler, MD
JAMA. 1998;279:663-668.
Context.— There is concern in both the medical community and the general public about mechanisms of medical decision making and the interplay of physician and insurer decisions in determining access to care.
Objective.— To examine the medical process influencing access to growth hormone (GH) therapy for childhood short stature by comparing coverage policies of US insurers with the treatment recommendations of US physicians.
Design and Participants.— Independent national representative surveys were mailed to insurers (private, Blue Cross/Blue Shield, health maintenance organizations, programs for Children with Special Health Care Needs, and Medicaid programs, n=113), primary care physicians (n=1504), and pediatric endocrinologists (n=534) with response rates of 75%, 60%, and 81%, respectively. Each survey included identical case scenarios. Primary care physicians were asked decisions about referrals to pediatric endocrinologists. Endocrinologists were asked GH treatment recommendations. Insurers were asked coverage decisions for GH therapy.
Main Outcome Measures.— Insurer coverage decisions for GH in specific case scenarios were compared with the recommendations of primary care physicians and pediatric endocrinologists.
Results.— Physician recommendations and insurance coverage decisions differed strikingly. For example, while 96% of pediatric endocrinologists recommended GH therapy for children with Turner syndrome, insurer policies covered GH therapy for only 52% of these children. Overall, referral and treatment decisions by physicians resulted in recommendations for GH therapy in 78% of children with GH deficiency, Turner syndrome, or renal failure; of those recommended for treatment, 28% were denied coverage by insurers. Similarly, GH therapy would be recommended by physicians for only 9% of children with idiopathic short stature, but insurers would not cover GH for the vast majority of these children. Furthermore, the data indicated considerable variation among insurers regarding coverage policies for GH (P<.01).
Conclusions.— Access to GH therapy differs depending on the type of insurance coverage. The deep discord between physician recommendations and insurance coverage decisions, exemplified by these findings, represents a major challenge to mechanisms of health care decision making, access, and costs.
From the Departments of Pediatrics (Drs Cuttler and Finkelstein and Ms Marrero), Pharmacology (Dr Cuttler), and Epidemiology and Biostatistics (Drs Finkelstein and Neuhauser), School of Medicine, and the Weatherhead School of Management (Dr Silvers), Case Western Reserve University, Cleveland, Ohio.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Physician Recommendations vs Insurance Coverage for Growth Hormone
Joseph I. Berman, Lynn-Georgia Tesch, Robert J. Yaes, Leona Cuttler, Beth S. Finkelstein, J. B. Silvers, Duncan Neuhauser, Ursula Marrero, James E. Sabin, and Norman Daniels
JAMA. 1998;280(12):1052-1054.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Making Insurance Coverage for New Technologies Reasonable and Accountable
James E. Sabin and Norman Daniels
JAMA. 1998;279(9):703-704.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Association of Socioeconomic Position and Medical Insurance With Fetal Diagnosis of Critical Congenital Heart Disease
Peiris et al.
Circ Cardiovasc Qual Outcomes 2009;2:354-360.
ABSTRACT
| FULL TEXT
Epistasis between Loci on Chromosomes 2 and 6 Influences Human Height
Liu et al.
J. Clin. Endocrinol. Metab. 2006;91:3821-3825.
ABSTRACT
| FULL TEXT
Growth Hormone Treatment for Idiopathic Short Stature: Implications for Practice and Policy
Cuttler and Silvers
Arch Pediatr Adolesc Med 2004;158:108-110.
FULL TEXT
Persistent Short Stature, Other Potential Outcomes, and the Effect of Growth Hormone Treatment in Children Who Are Born Small for Gestational Age
Lee et al.
Pediatrics 2003;112:150-162.
FULL TEXT
Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature: A Meta-analysis
Finkelstein et al.
Arch Pediatr Adolesc Med 2002;156:230-240.
ABSTRACT
| FULL TEXT
Management of multiple sclerosis across managed care and fee-for-service systems
Vickrey et al.
Neurology 2000;55:1341-1349.
ABSTRACT
| FULL TEXT
Who Should Determine When Health Care is Medically Necessary?
Rosenbaum et al.
NEJM 1999;340:229-232.
FULL TEXT
Physician Recommendations vs Insurance Coverage for Growth Hormone
Berman et al.
JAMA 1998;280:1052-1054.
FULL TEXT
Growth Hormone Therapy: Physicians vs. Insurers
JWatch Psychiatry 1998;1998:20-20.
FULL TEXT
Physician Recommendations vs. Insurer Coverage for Growth Hormone Therapy
JWatch General 1998;1998:5-5.
FULL TEXT
Making Insurance Coverage for New Technologies Reasonable and Accountable
Sabin and Daniels
JAMA 1998;279:703-704.
FULL TEXT
|
